Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

Shire announces third quarter 2009 financial results News-Medical.net We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth ... and more »

Shire Continues to Deliver Excellent Growth From Core Products SunHerald.com (press release) We have also continued to grow VYVANSE's market share which is now 13.4%, benefiting from both the 'back to school' season and strong 10% ADHD market growth ...

REG-Shire plc: 3rd Quarter Results Reuters We have also continued to grow vyvanse's market share which is now 13.4%, benefiting from both the `back to school' season and strong 10% ADHD market growth ... and more »

LONDON -(Dow Jones)- Shire PLC (SHP.LN) Wednesday said it hasn't seen any erosion of its newest hyperactivity drug Vyvanse's market share because of generic versions of an older drug.